These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Immunotherapy of cancer. Basic principles, possibilities, dangers, problems and conditions]. Meiss L; Romieu C; Serrou B Dtsch Med Wochenschr; 1973 Jun; 98(23):1179-85. PubMed ID: 4576228 [No Abstract] [Full Text] [Related]
3. [Immunotherapy of malignant tumors in man]. Govalle VI Vopr Onkol; 1976; 22(3):99-109. PubMed ID: 779262 [No Abstract] [Full Text] [Related]
4. Passive immunotherapy of cancer in animals and man. Rosenberg SA; Terry WD Adv Cancer Res; 1977; 25():323-88. PubMed ID: 326003 [No Abstract] [Full Text] [Related]
5. An insight into cancer immunology and immunotherapy. Thompson RB Prog Clin Pathol; 1975; 6():159-76. PubMed ID: 1105670 [No Abstract] [Full Text] [Related]
6. Partial tolerance and immunity after adoptive abrogation of transplantation tolerance in the rat. Elkins WL; Adams JS; Fox DH; Wilson DB; Stuart FP Cell Immunol; 1973 Dec; 9(3):412-25. PubMed ID: 4148477 [No Abstract] [Full Text] [Related]
7. Studies on transplantation of bone marrow and spleen cells. Munakata K Nagoya J Med Sci; 1966 Dec; 29(2):129-38. PubMed ID: 4862013 [No Abstract] [Full Text] [Related]
8. An introduction to tumor immunology and immunotherapy. Mitchell MS Gynecol Oncol; 1976 Mar; 4(1):1-12. PubMed ID: 791768 [No Abstract] [Full Text] [Related]
9. [Obstacles in the immunotherapy of cancer]. Ishibashi U Geka Chiryo; 1967 Nov; 17(5):515-21. PubMed ID: 4877442 [No Abstract] [Full Text] [Related]
10. [REDUCTION OF THE PLASMA CONCENTRATION OF THE CHARLOTTE FRIEND LEUKEMOGENIC VIRUS BY ADOPTIVE IMMUNOTHERAPY (GRAFT OF ALLOGENIC BONE MARROW)]. MATHE G; AMIEL JL C R Hebd Seances Acad Sci; 1964 Dec; 259():4408-10. PubMed ID: 14256003 [No Abstract] [Full Text] [Related]
11. [Adoptive local immunotherapy of the BP 8 ascites tumor in mice]. Mathé G Rev Fr Etud Clin Biol; 1966 Dec; 11(10):1027-9. PubMed ID: 5979830 [No Abstract] [Full Text] [Related]
12. Transplantation of bone marrow in refractory marrow failure and neoplastic diseases. Storb R; Thomas ED; Buckner CD; Clift RA; Fefer A; Glucksberg H; Neiman PE Am J Clin Pathol; 1974 Aug; 62(2):212-7. PubMed ID: 4602087 [No Abstract] [Full Text] [Related]
13. Bone-marrow transplantation in France, 1958-1973. Mathé G; Schwarzenberg L Transplant Proc; 1974 Dec; 6(4):335-43. PubMed ID: 4155150 [No Abstract] [Full Text] [Related]
14. Use of an immunoisolation device for cell transplantation and tumor immunotherapy. Geller RL; Loudovaris T; Neuenfeldt S; Johnson RC; Brauker JH Ann N Y Acad Sci; 1997 Dec; 831():438-51. PubMed ID: 9616733 [No Abstract] [Full Text] [Related]
15. [Problems of the immunotherapy of malignant neoplasma]. Trapeznikov NN; Iavorskiĭ VV Klin Med (Mosk); 1975 May; 52(5):15-22. PubMed ID: 1094178 [No Abstract] [Full Text] [Related]
16. [Pros and cons of the use of immunotherapeutic procedures with special reference to adoptive immunotherapy in proliferative diseases]. Schneiberg K Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(3):337-57. PubMed ID: 6159273 [TBL] [Abstract][Full Text] [Related]
17. [Effect of antilymphocyte serum on the redifferentiation of hematopoietic stem cells by syngeneic lymphocytes]. Golovistikov IN; Bliakher MS; Zykov IuV Dokl Akad Nauk SSSR; 1972 Jun; 204(4):980-2. PubMed ID: 4557586 [No Abstract] [Full Text] [Related]
18. Role of the hemoporetic inductive microenvironments (HIM) in xenogeneic bone marrow transplantation. Rauchwerger JM; Gallagher MT; Trentin JJ Transplantation; 1973 Jun; 15(6):610-3. PubMed ID: 4146021 [No Abstract] [Full Text] [Related]
19. Cell-mediated immunity and blocking serum activity before and after breakage of allograft tolerance in rats. Bansal SC; Hellström I; Hellström KE; Wright PW Transplantation; 1973 Dec; 16(6):610-20. PubMed ID: 4585385 [No Abstract] [Full Text] [Related]